These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 28824054

  • 1. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.
    Kurahashi K, Endo I, Kondo T, Morimoto K, Yoshida S, Kuroda A, Aihara KI, Matsuhisa M, Nakajima K, Mizobuchi Y, Nagahiro S, Abe M, Fukumoto S.
    Intern Med; 2017 Sep 15; 56(18):2455-2461. PubMed ID: 28824054
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
    Yin J, Su CB, Xu ZQ, Yang Y, Ma WB, Tao W, Yang Z, Xia XW.
    Chin Med Sci J; 2005 Mar 15; 20(1):23-6. PubMed ID: 15844307
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
    Barakat S, Melmed S.
    Arch Intern Med; 1989 Jun 15; 149(6):1443-5. PubMed ID: 2730266
    [Abstract] [Full Text] [Related]

  • 9. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L.
    Neuroendocrinology; 2004 Mar 15; 79(3):142-8. PubMed ID: 15103227
    [Abstract] [Full Text] [Related]

  • 10. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
    Waśko R, Bolko P, Kostrzewski J, Horst-Sikorska W, Liebert W, Sowiński J.
    Pol Arch Med Wewn; 2001 Aug 15; 106(2):693-8. PubMed ID: 11926144
    [Abstract] [Full Text] [Related]

  • 11. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
    Shimon I, Nass D, Hadani M.
    Pituitary; 2000 May 15; 2(4):289-94. PubMed ID: 11081151
    [Abstract] [Full Text] [Related]

  • 12. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov 15; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM.
    J Clin Endocrinol Metab; 2002 Oct 15; 87(10):4554-63. PubMed ID: 12364434
    [Abstract] [Full Text] [Related]

  • 17. Improvement of acromegaly after octreotide LAR treatment.
    Mangupli R, Lisette A, Ivett C, Paul C, de los Ríos Victoria C, Luis CJ.
    Pituitary; 2003 Oct 15; 6(1):29-34. PubMed ID: 14674721
    [Abstract] [Full Text] [Related]

  • 18. [Novel pharmacologic therapies in acromegaly].
    Góth M, Hubina E, Kovács L, Szabolcs I.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
    Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T.
    Endocr J; 2006 Feb 12; 53(1):125-32. PubMed ID: 16543682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.